Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation.

Benz, Alexander P; Hohnloser, Stefan H; Eikelboom, John W; Carnicelli, Anthony P; Giugliano, Robert P; Granger, Christopher B; Harrington, Josephine; Hijazi, Ziad; Morrow, David A; Patel, Manesh R; Seiffge, David J; Shoamanesh, Ashkan; Wallentin, Lars; Yi, Qilong; Connolly, Stuart J (2023). Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. European Heart Journal, 44(20), pp. 1807-1814. Oxford University Press 10.1093/eurheartj/ehad200

[img] Text
ehad200.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (543kB) | Request a copy

AIMS

The prognosis of patients with atrial fibrillation (AF) and ischemic stroke while taking oral anticoagulation is poorly understood. This study aimed to characterize the outcomes of patients following a stroke event while on oral anticoagulation.

METHODS AND RESULTS

Individual participant data from five pivotal randomized trials of antithrombotic therapy in AF were used to assess the outcomes of patients with a post-randomization ischemic stroke while on study medication (warfarin, standard-, or lower-dose direct oral anticoagulant regimen) during trial follow-up. The primary outcome was recurrent ischemic stroke after the first post-randomization ischemic stroke. The primary analysis included 1163 patients with a first post-randomization ischemic stroke while on study medication (median age 73 years, 39.3% female, 35.4% history of stroke before trial enrollment). During a median continued follow-up of 337 days, 74 patients had a recurrent ischemic stroke [cumulative incidence at 1 year: 7.0%, 95% confidence interval (CI) 5.2%-8.7%]. The cumulative incidence of mortality at 3 months after stroke was 12.4% (95% CI 10.5%-14.4%). Consistent results for the incidence of recurrent ischemic stroke at 1 year were obtained in an analysis accounting for the competing risk of death (6.2%, 95% CI 4.8%-7.9%) and in a landmark analysis excluding the first 2 weeks after the index stroke and only including patients without permanent study drug discontinuation since then (6.8%, 95% CI 4.6%-8.9%).

CONCLUSION

Patients with AF and ischemic stroke while on oral anticoagulation are at increased risk of recurrent ischemic stroke and death. These patients currently have an unmet medical need.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Seiffge, David Julian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0195-668X

Publisher:

Oxford University Press

Language:

English

Submitter:

Pubmed Import

Date Deposited:

12 Apr 2023 08:05

Last Modified:

22 May 2023 00:15

Publisher DOI:

10.1093/eurheartj/ehad200

PubMed ID:

37038327

Uncontrolled Keywords:

Atrial fibrillation DOAC Ischemic stroke Oral anticoagulation Recurrence Warfarin

BORIS DOI:

10.48350/181663

URI:

https://boris.unibe.ch/id/eprint/181663

Actions (login required)

Edit item Edit item
Provide Feedback